TickerFacts.

Autolus Therapeutics plc (AUTL): Revenue

Annual figures by period end, from SEC filings.

$75.39M
Year ended 2025-12-31
$117.39M
Trailing 12 months to 2026-06-30
2016-09-30: $1.21M2017-09-30: $1.69M2018-09-30: $1.41M2019-12-31: $2.91M2023-12-31: $1.70M2024-12-31: $10.12M2025-12-31: $75.39M$75.39M
2016-09-30 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$75.39M+644.9%2026-03-27, From 2025-01-01
2024-12-31$10.12M+496.0%2026-03-27, From 2024-01-01
2023-12-31$1.70Mn/a2025-03-20, From 2023-01-01
No annual figure between 2019-12-31 and 2023-12-31.
2019-12-31$2.91Mn/a2020-03-03, From 2019-01-01
No annual figure between 2018-09-30 and 2019-12-31.
2018-09-30$1.41M-16.9%2020-03-03, From 2017-10-01
2017-09-30$1.69M+39.7%2020-03-03, From 2016-10-01
2016-09-30$1.21Mn/a2019-02-25, From 2015-10-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Autolus Therapeutics plc (AUTL)2025-12-31$75.39M+644.9%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$74.68M+26.9%
Compugen Ltd (CGEN)2025-12-31$72.76M+161.1%
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$70.00Mn/a
MeiraGTx Holdings plc (MGTX)2025-12-31$81.39M+144.6%
Vir Biotechnology, Inc. (VIR)2025-12-31$68.56M-7.6%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$85.21Mn/m
Champions Oncology, Inc. (CSBR)2026-04-30$59.42M+4.4%
Sutro Biopharma, Inc. (STRO)2025-12-31$102.48M+65.2%

Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗